Jay A. Berzofsky et al. Appl. No.: Unassigned

Parent Appl. No.: 09/508,552

## **REMARKS**

In the parent application (USSN 09/508,552), the Examiner set forth the following revised restriction requirement in Paper No. 9: Group II consisting of claims 1-16, 21, 22, 25-37, 42, 43, and 46-69 and drawn to a composition and method of using HIV-1 antigen, SEQ ID NO:2 was elected for prosecution in the parent application.

Applicants have amended claims 21 and 42 and canceled claims 22 and 43 to remove all reference to the HIV-1 antigen having SEQ ID NO:2 and its use in a composition and methods of the present invention.

## **CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

By:

Respectfully submitted,

Dated: 30 Mud 2004

Brian W. Po

Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 206-467-9600 Fax: 415-576-0300

BWP:jms 60163630 v1